In Vitro Non-Genomic Effects of Calcifediol on Human Preosteoblastic Cells.
Donati S., Palmini G., Romagnoli C., Aurilia C., Miglietta F., Falsetti I.
Laboratory Study, published in Nutrients (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Nutrients (2021)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 34959778
- DOI
- 10.3390/nu13124227
Abstract (original English)
Several recent studies have demonstrated that the direct precursor of vitamin D 3 , the calcifediol [25(OH)D 3 ], through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Considering that itself may function as a VDR ligand, although with a lower affinity, respect than the active form of vitamin D, we have assumed that 25(OH)D 3 by binding the VDR could have a vitamin's D 3 activity such as activating non-genomic pathways, and in particular we selected mesenchymal stem cells derived from human adipose tissue (hADMSCs) for the in vitro assessment of the intracellular Ca 2+ mobilization in response to 25(OH)D 3 . Our result reveals the ability of 25(OH)D 3 to activate rapid, non-genomic pathways, such as an increase of intracellular Ca 2+ levels, similar to what observed with the biologically active form of vitamin D 3 . hADMSCs loaded with Fluo-4 AM exhibited a rapid and sustained increase in intracellular Ca 2+ concentration as a result of exposure to 10 -5 M of 25(OH)D 3 . In this work, we show for the first time the in vitro ability of 25(OH)D 3 to induce a rapid increase of intracellular Ca 2+ levels in hADMSCs. These findings represent an important step to better understand the non-genomic effects of vitamin D 3 and its role in endocrine system.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.